Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
- Conditions
- TuberculosisHIV Infections
- Registration Number
- NCT00000950
- Brief Summary
The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.
- Detailed Description
Patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two are isoniazid, rifampin, pyrazinamide, or ethambutol. Blood specimens are collected at 2, 6, and 10 hours after administration of study medication, once between Days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen (twice weekly or three times weekly).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Univ of Southern California / LA County USC Med Ctr
🇺🇸Los Angeles, California, United States
Harbor UCLA Med Ctr
🇺🇸Torrance, California, United States
University of Miami (Pediatric)
🇺🇸Miami, Florida, United States
Emory Univ
🇺🇸Atlanta, Georgia, United States
Queens Med Ctr
🇺🇸Honolulu, Hawaii, United States
Univ of Hawaii
🇺🇸Honolulu, Hawaii, United States
Tulane Univ School of Medicine
🇺🇸New Orleans, Louisiana, United States
SUNY / Health Sciences Ctr at Brooklyn
🇺🇸Brooklyn, New York, United States
Beth Israel Med Ctr
🇺🇸New York, New York, United States
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
🇺🇸New York, New York, United States
Scroll for more (3 remaining)Univ of Southern California / LA County USC Med Ctr🇺🇸Los Angeles, California, United States